{"entity":{"id":"nct04995523","kind":"trial","name":"A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC","aka":[],"tldr":"A phase 1/2 trial of Rilvegostomig in non-small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.","summary":"A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC is a phase 1/2 interventional study registered as NCT04995523 by AstraZeneca, with 212 participants enrolled, started 2021-09-14 and due to reach its primary completion in 2026-08-28. Interventions recorded: AZD2936.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04995523","url":"https://clinicaltrials.gov/study/NCT04995523"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["rilvegostomig"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04995523","phase":"1/2","setting":"Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC","sponsor":"AstraZeneca","enrolled":212,"outcomes":[]},"route":"/trials/nct04995523/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"rilvegostomig","kind":"drug","name":"Rilvegostomig","route":"/drugs/rilvegostomig/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}